You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Sunitinib Malate for Gastrointestinal Stromal Tumour (GIST) in Imatinib Mesylate Resistant Patients

Version: 2 ID: 11-8 Oct 2015
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Authors:
Sarcoma Disease Site Group

Patient Population

Adult patients with unresectable or metastatic/recurrent GIST who have been previously treated with, and subsequently developed resistance or intolerance to IM.

Intended Guideline Users

Clinicians directly involved in the treatment of the target population.

Research Question(s)

Is sunitinib malate (marketed as Sutent) superior to placebo or other intervention for primary outcomes of interest in adult patients with gastrointestinal stromal tumour(s) who have developed resistance or exhibit intolerance to imatinib mesylate?

pdf download Full Report (PDF) (578.5 KB)